# Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)

Study · id `cardio:ct-nct04275323` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04275323](<https://clinicaltrials.gov/study/NCT04275323>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04275323

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

## Technical summary

Registry record NCT04275323. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-02 (actual); primary completion 2024-06-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 302 participants (enrolled count; ClinicalTrials.gov record NCT04275323, source copy `cardio:ctgov-nct04275323-2024-09-19`, retrieved 2026-10-31)
- Started: 2019-08-02 (actual) (ClinicalTrials.gov record NCT04275323, source copy `cardio:ctgov-nct04275323-2024-09-19`, retrieved 2026-10-31)
- Primary completion: 2024-06-03 (actual) (ClinicalTrials.gov record NCT04275323, source copy `cardio:ctgov-nct04275323-2024-09-19`, retrieved 2026-10-31)
- Completion: 2024-06-03 (actual) (ClinicalTrials.gov record NCT04275323, source copy `cardio:ctgov-nct04275323-2024-09-19`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04275323, source copy `cardio:ctgov-nct04275323-2024-09-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04275323-2024-09-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)
- Condition: Arterial Occlusive Disease
- Condition: Ischemia
- Condition: Ulcers
- Condition: Peripheral Vascular Disease
- Intervention (Genetic): NL003
- Intervention (Other): Normal Saline
- Lead sponsor: Beijing Northland Biotech. Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Beijing Northland Biotech. Co., Ltd. (`cardio:org-beijing-northland-biotech-co-ltd`)

## Provenance

Content hash: 7446e8b8f86a74eec5de27f4d6ce8db51371d6e776adb696cc8bcde2514fd145
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
